Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials

Luigi Celio, Erminio Bonizzoni, Emilio Bajetta, Silvia Sebastiani, Tania Perrone, Matti S. Aapro

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalSupportive Care in Cancer
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Anthracyclines
Cyclophosphamide
Nausea
Dexamethasone
Vomiting
Meta-Analysis
Drug Therapy
Antiemetics
Breast Neoplasms
palonosetron

Keywords

  • AC-containing chemotherapy
  • Breast cancer
  • CINV
  • Dexamethasone
  • Meta-analysis
  • Palonosetron

ASJC Scopus subject areas

  • Oncology

Cite this

@article{b0ce7227aa0a4cb194272be79e941679,
title = "Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials",
abstract = "Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-na{\"i}ve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (",
keywords = "AC-containing chemotherapy, Breast cancer, CINV, Dexamethasone, Meta-analysis, Palonosetron",
author = "Luigi Celio and Erminio Bonizzoni and Emilio Bajetta and Silvia Sebastiani and Tania Perrone and Aapro, {Matti S.}",
year = "2013",
month = "2",
doi = "10.1007/s00520-012-1558-9",
language = "English",
volume = "21",
pages = "565--573",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy

T2 - Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials

AU - Celio, Luigi

AU - Bonizzoni, Erminio

AU - Bajetta, Emilio

AU - Sebastiani, Silvia

AU - Perrone, Tania

AU - Aapro, Matti S.

PY - 2013/2

Y1 - 2013/2

N2 - Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (

AB - Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (

KW - AC-containing chemotherapy

KW - Breast cancer

KW - CINV

KW - Dexamethasone

KW - Meta-analysis

KW - Palonosetron

UR - http://www.scopus.com/inward/record.url?scp=84874115358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874115358&partnerID=8YFLogxK

U2 - 10.1007/s00520-012-1558-9

DO - 10.1007/s00520-012-1558-9

M3 - Article

C2 - 22869054

AN - SCOPUS:84874115358

VL - 21

SP - 565

EP - 573

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -